Biocept (BIOC) Stock Price, News & Analysis

Company Overview

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.43 to $1.67
• 52-Week Range: N/A
• Volume: 751,400 shs
• Average Volume: 764,067 shs
• Market Capitalization: $1.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BIOC Stock Analysis - Frequently Asked Questions

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its earnings results on Monday, November, 15th. The medical research company reported $0.90 EPS for the quarter, missing the consensus estimate of $2.70 by $1.80. The medical research company earned $17.47 million during the quarter, compared to analyst estimates of $16.87 million.

When did Biocept's stock split?

Biocept's stock reverse split before market open on Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biocept investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Vaxart (VXRT), NIO (NIO) and iBio (IBIO).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BIOC
• CIK: 1044378
• Web: www.biocept.com
• Phone: (858) 320-8200
• Fax: 858-320-8225
• Employees: 50
• Year Founded: 1993

Profitability

• EPS (Most Recent Fiscal Year): ($58.4549)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.09 million
• Net Margins: N/A
• Pretax Margin: -564.02%
• Return on Equity: -468.87%
• Return on Assets: -118.41%

Debt

• Debt-to-Equity Ratio: 2.88
• Current Ratio: 1.81
• Quick Ratio: 1.70

Sales & Book Value

• Annual Sales: $25.86 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.60 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,630,000
• Free Float: 2,584,000
• Market Cap: $1.14 million
• Optionable: Not Optionable
• Beta: 0.69